Silence Therapeutics and Mallinckrodt Submit Clinical Trial Application for SLN501 to Treat Complement-Mediated Diseases
Shots:
- Silence to receive $3M in research milestone & is responsible for preclinical activities & development of each target for SLN501. Mallinckrodt will be responsible for clinical development & global commercialization
- The collaboration will use Silence’s mRNAi GOLD platform to develop siRNAs for complement-mediated diseases. The P-I study is expected to be initiated in H1’22
- Upon the 2019 collaboration with Mallinckrodt, Silence received $20M up front for an exclusive license globally to siRNAs developed against 1 complement target, C3 & gets an options to license siRNAs against ~2 additional complement targets at $2M/target, and~$2B in milestone for 3 targets along with royalties for each product
Ref: Business Wire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
